March 24, 2026 —
Neurogene Inc. has reported significant progress in the clinical development of NGN-401, its investigational AAV9-based gene therapy for Rett syndrome, a rare and severe neurodevelopmental disorder. The company announced that 100% of participants have now been enrolled in the Embolden™ registrational trial, with more than half already dosed, and remains on track to complete dosing in the second quarter of 2026.
NGN-401 is designed as a one-time AAV9 gene therapy that delivers a full-length functional copy of the MECP2 gene, mutations of which are the primary cause of Rett syndrome. The therapy incorporates Neurogene’s proprietary EXACT™ transgene regulation technology, which is intended to maintain tightly controlled and consistent expression of the MeCP2 protein across individual cells. This regulation is particularly important because both insufficient and excessive MECP2 expression can lead to neurological dysfunction.
The therapy is administered via intracerebroventricular (ICV) delivery, enabling the AAV9 vector to distribute broadly across the central nervous system. Preclinical biodistribution studies suggest that this approach may allow widespread targeting of brain and spinal cord cells, which are critically affected in Rett syndrome.
Clinical data to date indicate that NGN-401 has been generally well tolerated at the 1×10¹⁵ vector genome (vg) dose, with no reported cases of hemophagocytic lymphohistiocytosis (HLH) in either the Phase 1/2 trial or the ongoing Embolden registrational study as of March 2026. Additional interim data from the Phase 1/2 trial—including both pediatric and adolescent/adult cohorts—are expected in mid-2026, with at least 12 months of follow-up available for all enrolled participants.
Earlier interim results from the pediatric cohort (ages 4–10) demonstrated durable, multidomain developmental improvements, including continued acquisition of developmental milestones over time. These encouraging findings contributed to the U.S. Food and Drug Administration granting Breakthrough Therapy designation to NGN-401, reflecting the therapy’s potential to address a serious condition with limited treatment options.
Neurogene is also preparing for potential commercialization. The company confirmed with the FDA that commercial manufacturing scale will match the current clinical manufacturing process, eliminating the need for additional comparability studies. In addition, Process Performance Qualification (PPQ) campaigns are expected to begin in mid-2026, supporting future Biologics License Application (BLA) readiness.
Operational preparations are also underway to support a potential launch. All 13 U.S. clinical trial sites participating in the Embolden study have been activated, with ongoing plans to transition these sites into commercial treatment centers should the therapy receive regulatory approval.
From a financial perspective, Neurogene reported $269 million in cash, cash equivalents, and short-term investments as of December 31, 2025, which the company expects will fund operations through the first quarter of 2028. The company also reported $75.0 million in research and development expenses for 2025, reflecting increased investment in clinical trials and program development for Rett syndrome.
Looking ahead, key milestones for 2026 include completing dosing in the Embolden trial, presenting updated clinical data from ongoing studies, initiating the PPQ manufacturing campaign, and continuing early commercial-readiness activities.
If successful, NGN-401 could represent a transformative AAV gene therapy for Rett syndrome, offering the possibility of a one-time treatment that addresses the underlying genetic cause of the disease.
